Tags

Type your tag names separated by a space and hit enter

Pharmacotherapeutic options for the treatment of depression in patients with chronic kidney disease.
Nephrol Nurs J. 2008 May-Jun; 35(3):257-263; quiz 264.NN

Abstract

Depressive disorders occur in up to one-third of patients with chronic kidney disease CKD). First-line pharmacologic treatments include selective serotonin reuptake inhibitors and second generation agents, such as bupropion, mirtazapine, and venlafaxine. Although very little research has been conducted on the use of antidepressants in CKD, health care providers should be aware of renal dose adjustments for these agents, drug interactions, and potential adverse effects. This article reviews the epidemiology and significance of depression in patients with CKD and discusses drug therapy options for treatment of depression in this patient population.

Authors+Show Affiliations

Manitoba Renal Program, Department of Pharmaceutical Services, Health Sciences Centre Hospital, Winnipeg, Manitoba, Canada.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18649586

Citation

Raymond, Colette B., et al. "Pharmacotherapeutic Options for the Treatment of Depression in Patients With Chronic Kidney Disease." Nephrology Nursing Journal : Journal of the American Nephrology Nurses' Association, vol. 35, no. 3, 2008, pp. 257-263; quiz 264.
Raymond CB, Wazny LD, Honcharik PL. Pharmacotherapeutic options for the treatment of depression in patients with chronic kidney disease. Nephrol Nurs J. 2008;35(3):257-263; quiz 264.
Raymond, C. B., Wazny, L. D., & Honcharik, P. L. (2008). Pharmacotherapeutic options for the treatment of depression in patients with chronic kidney disease. Nephrology Nursing Journal : Journal of the American Nephrology Nurses' Association, 35(3), 257-263; quiz 264.
Raymond CB, Wazny LD, Honcharik PL. Pharmacotherapeutic Options for the Treatment of Depression in Patients With Chronic Kidney Disease. Nephrol Nurs J. 2008 May-Jun;35(3):257-263; quiz 264. PubMed PMID: 18649586.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacotherapeutic options for the treatment of depression in patients with chronic kidney disease. AU - Raymond,Colette B, AU - Wazny,Lori D, AU - Honcharik,Patricia L, PY - 2008/7/25/pubmed PY - 2008/9/20/medline PY - 2008/7/25/entrez SP - 257-263; quiz 264 JF - Nephrology nursing journal : journal of the American Nephrology Nurses' Association JO - Nephrol Nurs J VL - 35 IS - 3 N2 - Depressive disorders occur in up to one-third of patients with chronic kidney disease CKD). First-line pharmacologic treatments include selective serotonin reuptake inhibitors and second generation agents, such as bupropion, mirtazapine, and venlafaxine. Although very little research has been conducted on the use of antidepressants in CKD, health care providers should be aware of renal dose adjustments for these agents, drug interactions, and potential adverse effects. This article reviews the epidemiology and significance of depression in patients with CKD and discusses drug therapy options for treatment of depression in this patient population. SN - 1526-744X UR - https://www.unboundmedicine.com/medline/citation/18649586/Pharmacotherapeutic_options_for_the_treatment_of_depression_in_patients_with_chronic_kidney_disease_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=18649586.ui DB - PRIME DP - Unbound Medicine ER -